On September 1, 2021, Aimed Alliance submitted a comment to Senators Schumer, Wyden, and Booker on the Discussion Draft: Cannabis Administration and Opportunity Act (CAOA). The CAOA would remove cannabidiol from the Controlled Substances Act and transfer jurisdiction over cannabidiol products to the Bureau of Alcohol, Tobacco and Firearms (ATF), the Tobacco Tax and Trade Bureau (TTB), and the U.S. Food and Drug Administration (FDA). The CAOA would also reinvest in communities that have been most impacted by cannabis criminalization; create a regulatory pathway for FDA-approved CBD products; and allow some CBD products to be sold as dietary supplements.
In our comment, we called on Congress to (1) ensure racial justice through cannabis regulation; (2) create an appropriate regulatory pathway for non-FDA-approved cannabidiol (CBD) products to ensure the products are safe and effective; (3) preserve and expand the FDA’s jurisdiction over cannabis products; (4) implement strong safety requirements for cannabis products; and (5) prevent misleading marketing activities. Read our comment here.
Click here to read the CAOA Discussion Draft.
Last Updated on September 7, 2021 by Aimed Alliance
